TrueCAGR

Apollo Hospitals Enterprises Ltd.

NSE: APOLLOHOSPBSE: 508869ISIN INE437A01024Face value ₹5standalone
₹9,190
+5.09% · 2026-11-20 · 52-wk ₹6,794–₹9,190
Source: BSE filings · Financials to FY2026 · 5 years of history · Data last updated: results filed 4 Nov 2026, prices to 20 Nov 2026 · How we calculate thisconsolidatedstandalone
Section 02 · Synthesis

What stands out?

The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.

StrengthConcernWatchContext
StrengthTalking point

Profit outpacing revenue

Profit grew 33.1% while revenue grew 15.8%, so the company kept more of each rupee of revenue as profit.

Net profit growth+33.1%Revenue growth+15.8%

Importance 64 / 95 · growth

StrengthTalking point

Returns at a multi-year high

ROE of 21.5% is the highest in 4 years (prior range 13.5% to 18.8%).

Importance 56 / 95 · profitability

StrengthTalking point

Compounding revenue

Revenue compounded at 14.5% a year over 4 years (₹14,663 → ₹25,229).

Importance 55 / 95 · growth

Section 03 · The company

Who is this company?

Classified by the exchange under Healthcare › Healthcare › Healthcare Services › Hospital.

Market cap
₹1.32 L cr
FY2026 revenue
₹9,326 cr
FY2026 net profit
₹1,493 cr
Net worth
₹9,963 cr
Total debt
₹1,822 cr
EPS (basic)
₹103.81
Listed
NSE · BSE
Reporting
Ind-ASApr–Mar

Peer set used on this page: 3 hospital.

Section 04 · Business performance

Is the business growing?

Revenue grew 11.2% a year over 4 years, from ₹6,098 cr in FY2022 to ₹9,326 cr in FY2026. Net profit grew 22.4% a year over the same period.

Revenue & net profit — FY22 to FY26₹ crore · consolidated
₹'000 cr035810012REVENUENET PROFIT6k665FY227k1,085FY237k1,011FY248k1,296FY259k1,493FY26
RevenueNet profit
Strength

Profit grew 33.1% while revenue grew 15.8%, so the company kept more of each rupee of revenue as profit.

Rule PROFIT_FASTER_THAN_REVENUE

Revenue growth per year
+11.2%over 4 years (FY22–FY26)
Revenue growth
+13.7%vs last year
Net profit growth
+15.1%vs last year
Change in net profit since FY22
+124%

Revenue compounded at 14.5% a year over 4 years (₹14,663 → ₹25,229).

Net profit grew 33.1% year on year (FY2025 → FY2026).

Revenue grew 15.8% year on year (FY2025 → FY2026).

Section 05 · Recent activity

What changed recently?

In Q2 FY27 (Jul–Sep 2026), revenue was ₹7,615 cr (up 20.8% on the same quarter last year) and net profit ₹660 cr (up 33.5%).

Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.

Strength

Q2 FY27 net profit was ₹660 cr, up 33.5% from ₹494 cr a year earlier.

Rule QTR_PROFIT_GROWTH_YOY

Strength

Q2 FY27 revenue was ₹7,615 cr, up 20.8% from ₹6,304 cr in Q2 FY26 a year earlier.

Rule QTR_REVENUE_GROWTH_YOY

Strength

Q2 FY27 EBIT was ₹1,005 cr, up 29.2% from ₹778 cr a year earlier.

Rule QTR_OPERATING_PERFORMANCE_CHANGE_YOY

A. Quarterly results

Latest quarters — Q3 '25 to Q2 '27₹ crore · consolidated
₹'000 cr02468001REVENUENET PROFIT6k379Q3 '256k415Q4 '256k441Q1 '266k494Q2 '266k516Q3 '267k551Q4 '267k610Q1 '278k660Q2 '27
RevenueNet profit
QuarterRevenueYoYNet profitYoYNet margin
Q3 FY255,527+13.9%379+49.1%6.9%
Q4 FY255,592+13.1%415+60.4%7.4%
Q1 FY265,842+14.9%441+39.8%7.5%
Q2 FY266,304+12.8%494+24.8%7.8%
Q3 FY266,477+17.2%516+36.1%8.0%
Q4 FY266,606+18.1%551+33.0%8.3%
Q1 FY277,044+20.6%610+38.4%8.7%
Q2 FY277,615+20.8%660+33.5%8.7%

B. TTM snapshot

Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters

Revenue
₹27,741 crTTM
EBITDA
₹4,450 crTTM
EBIT
₹3,541 crTTM
PBT
₹3,055 crTTM
Net profit
₹2,338 crTTM

C. Corporate actions

14 Aug 2026DividendFinal Dividend - Rs. - 10.0000 — ₹10.00/share
16 Feb 2026DividendInterim Dividend - Rs. - 10.0000 — ₹10.00/share
19 Aug 2025DividendFinal Dividend - Rs. - 10.0000 — ₹10.00/share
14 Feb 2025DividendInterim Dividend - Rs. - 9.0000 — ₹9.00/share
16 Aug 2024DividendFinal Dividend - Rs. - 10.0000 — ₹10.00/share
20 Feb 2024DividendInterim Dividend - Rs. - 6.0000 — ₹6.00/share
18 Aug 2023DividendFinal Dividend - Rs. - 9.0000 — ₹9.00/share
24 Feb 2023DividendInterim Dividend - Rs. - 6.0000 — ₹6.00/share
18 Aug 2022DividendDividend - Rs. - 11.7500 — ₹11.75/share
18 Aug 2021DividendDividend - Rs. - 3.0000 — ₹3.00/share
17 Sept 2020DividendFinal Dividend - Rs. - 2.7500 — ₹2.75/share
25 Feb 2020DividendInterim Dividend - Rs. - 3.2500 — ₹3.25/share
12 Sept 2019DividendDividend - Rs. - 6.0000 — ₹6.00/share
12 Sept 2018DividendDividend - Rs. - 5.0000 — ₹5.00/share
7 Sept 2017DividendDividend - Rs. - 6.0000 — ₹6.00/share
22 Mar 2016DividendInterim Dividend - Rs. - 6.0000 — ₹6.00/share
30 Jul 2015DividendDividend - Rs. - 5.7500 — ₹5.75/share
13 Aug 2014DividendDividend - Rs. - 5.7500 — ₹5.75/share
25 Jul 2013DividendDividend - Rs. - 5.5000 — ₹5.50/share
26 Jul 2012DividendDividend - Rs. - 4.0000 — ₹4.00/share
7 Jul 2011DividendDividend - Rs. - 3.7500 — ₹3.75/share
2 Sept 2010Stock splitStock Split From Rs.10/- to Rs.5/- — 10:5
15 Jul 2010DividendDividend - Rs. - 7.0000 — ₹7.00/share
20 Aug 2009DividendDividend - Rs. - 6.5000 — ₹6.50/share
11 Aug 2008DividendDividend - Rs. - 6.0000 — ₹6.00/share
Section 06 · Business performance

Is it becoming more profitable?

EBITDA margin was 28.9% in FY2026, against 24.0% in FY2022. ROE was 16.0% and ROCE 19.7% in FY2026.

Margins — FY22 to FY26% of revenue · consolidated
0%5%10%15%20%25%30%28.9%15.4%FY22FY23FY24FY25FY26
EBITDA marginNet margin
Strength

ROE of 21.5% is the highest in 4 years (prior range 13.5% to 18.8%).

Rule ROE_AT_MULTI_YEAR_HIGH

EBITDA margin now
28.9%
5-year range
24.0–29.2%
ROE FY2026
16.0%
ROCE FY2026
19.7%

ROE of 21.5% is well above the hospital median of 14.3%.

EBITDA margin of 15.7% is below the hospital median of 23.4%.

ROE improved from 18.8% to 21.5% year on year.

Section 07 · Financial health

Is financial health improving?

Debt-to-equity was 0.18x in FY2026, against 0.33x in FY2022; interest coverage 9.10x. Operating cash flow was 1.38x net profit.

Net worth — FY22 to FY26₹ crore · consolidated
₹'000 cr037106kFY227kFY238kFY249kFY2510kFY26
Net worth (shareholders' funds)
Strength

Net worth compounded at 14.0% a year over 4 years (₹5,899 → ₹9,975).

Rule NET_WORTH_COMPOUNDING

Operating cash flow vs net profit₹ crore · FY22–FY26
0k1k2k3k1k665FY221k1kFY231k1kFY242k1kFY252k1kFY26
Operating cash flowNet profit
Total debt
₹1,822 cr
Operating cash flow ÷ net profit
1.38×FY2026
Free cash flow
₹1,019 cr
Current ratio
1.74×

Operating cash flow has matched or exceeded reported profit in 5 of the last 5 profit-making years (latest 1.43×).

Free cash flow has been positive in 5 of the last 5 years.

Section 08 · Relative position

How does it compare with peers?

Within its 3-company Hospital peer group, it ranks 1 of 3 on return on equity and 3 of 3 on EBITDA margin. Its P/E of 56.5 compares with a peer median of 58.7.

Ranked against 3 hospital (FY2026, consolidated). No peer-relative rule fired for this company.

Revenue growth

APOLLOHOSP · 3rd of 3 · set median 17.3%

MAXHEALTH19.1%FORTIS17.3%APOLLOHOSP15.8%

EBITDA margin

APOLLOHOSP · 3rd of 3 · set median 23.4%

MAXHEALTH28.7%FORTIS23.4%APOLLOHOSP15.7%

Return on equity

APOLLOHOSP · 1st of 3 · set median 14.3%

APOLLOHOSP21.5%MAXHEALTH14.3%FORTIS11.0%

P/E ratio

APOLLOHOSP · 1st of 3 · set median 58.7×

APOLLOHOSP56.5×FORTIS58.7×MAXHEALTH76.1×
P / E
56.5×TTM to Sept 26
P / B
13.2×latest book
P / S
4.8×TTM sales
Earnings yield
1.8%TTM to Sept 26

On the trailing twelve months. Last full year: P/E 66.0× · P/S 5.2× · ROE 21.5%. TTM and full-year profit differ by more than 15% — a one-off in a recent quarter is moving the trailing figure; weigh it against the full year.

Section 09 · The stock

How has the stock performed?

The share price is up 23.8% over 1 year, up 68.1% over 3 years (18.9% a year) and up 64.4% over 5 years (10.5% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is at its 52-week high.

Adjusted close — 2020-01 to 2026-11₹ per share · split / bonus adjusted
0k4k8k₹9,1902020202120222023202420252026
Context

Over 4 years profit (15.9% a year) and the stock (18.9% a year) compounded at roughly the same rate.

Rule STOCK_TRACKED_EARNINGS

Business vs stock — 5-year compound annual rate
Net profit15.9%/yrShare price18.9%/yr
1-year return
+23.8%
3-year return
+68.1%
5-year return
+64.4%
From 52-wk high
0.0%
Section 10 · Technical data

What does the technical data say?

Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.

vs 50-day avg
Above₹8,399
vs 200-day avg
Above₹8,178
RSI (14)
71.1overbought
MACD histogram
78.5
From 52-wk high
0.0%
From 52-wk low
+35.3%
30-day volatility
31.5%ann.
6-month return
+13.7%
RSI (14) · 0–10071.1 — overbought
0305070100OVERSOLDOVERBOUGHT71.1
Section 11 · Open questions

What should I investigate further?

Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.

  • Concern
    Thinner margins than peers
    EBITDA margin of 15.7% is below the hospital median of 23.4%.
    MARGIN_BELOW_PEER_MEDIAN · conviction 47
Data coverage is complete — 5 years of financials (FY2022–FY2026), full P&L, balance sheet and cash-flow statement, sector metrics fully mapped.
Section 12 · Reference

The numbers

The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.

Income & balance sheet — ₹ crore, consolidated
MetricFY22FY23FY24FY25FY26
Revenue6,0986,5257,2748,2029,326
Total income6,1456,6767,4548,5509,698
EBITDA1,4661,8331,9772,3922,700
Profit before tax8521,2281,3291,6891,946
Net profit6651,0851,0111,2961,493
EPS (₹)46.375.570.3180.3103.8
Net worth6,1116,9257,7118,7349,963
Total debt2,0241,7611,9561,7831,822
Operating cash flow1,2011,2241,1911,7422,059
Free cash flow7438315728971,019
Key ratios — consolidated
RatioFY22FY23FY24FY25FY26
Growth
Revenue growth YoY—7.011.512.813.7
Profit growth YoY—63.1-6.828.315.1
Profitability
EBITDA margin %24.028.127.229.228.9
Net margin %10.816.213.615.215.4
Return on equity %10.916.613.815.816.0
Return on capital %13.617.417.219.219.7
Leverage & cash
Debt to equity0.330.250.250.200.18
Cash flow ÷ profit1.811.131.181.341.38
Current ratio2.912.532.682.441.74
Financials: BSE Integrated Filing inline XBRL (SEBI taxonomy), normalised to standard metric keys. Prices: end-of-day — history loaded from NSE end-of-day files, new days from the BSE bhavcopy; raw OHLC preserved; a corporate-action factor produces the adjusted series. The insight engine writes factual observations from fixed rules — it does not make recommendations. Not investment advice.